The GLP-1 Products and Players –Stocks to Watch
Stocks mentioned- Integrated Ventures, Inc. (OTCQB:
$INTV), Novo Nordisk (NYSE: $NVO), Eli Lilly and Company
(NYSE: $LLY), Hims & Hers Health, Inc., (NYSE: $HIMS),
Viking Therapeutics, Inc. (NASDAQ: $VKTX)
August 28, 2024 - Investorideas.com, a go-to investing platform covering health and
wellness and biotech stocks issues a snapshot looking at news and developments for
the global GLP-1 receptor agonist market, featuring new player in the market, Integrated
Ventures, Inc. (OTCQB: INTV).
According to Research and Markets, The
global GLP-1 receptor agonist market size is expanding at a CAGR of 21.65% from
2024 to 2030”
Continued: “The strong
product pipeline and formulation advancements are driving the market. In
addition, novel innovative products are booming the market. In September 2019,
Rybelsus, the first and only oral GLP-1 analog was approved by the U.S.FDA for
improving the glycemic control in type-2 diabetes patients. It is a
semaglutide-based product developed by Novo Nordisk (NYSE: NVO), which is currently under review by European
Medicines Agency (EMA) and Pharmaceuticals and Medical Devices Agency (PMDA).
After receiving the approval, the market may witness significant growth over
the forecast period.”
“Furthermore, pharmaceutical companies are focusing
on research collaborations for developing new GLP-1 products. For instance, in
September 2018, Eli Lilly and Company (NYSE: LLY) entered into a license agreement with Chugai
Pharmaceutical Co., Ltd for OWL833. OWL833 is Chugai's proprietary oral GLP-1
agonist candidate and as per the agreement Eli Lilly will obtain global
commercialization and development rights.”
Continued: “The Novo
Nordisk A/S (NYSE: NVO) Ozempic segment dominated the market and accounted for
a share of 37.77% in 2023. Ozempic is a brand-name U.S. FDA-approved
prescription drug used to treat adults with type 2 diabetes.”
Today, Integrated
Ventures, Inc. (OTCQB: INTV) announced its strategic entry into the
rapidly expanding health and wellness sector.
The initial phase of this transition
will be led by the newly established subsidiary, MedWell USA, LLC, which will
serve as a B2B Procurement Agent for a variety of pharmaceutical products, with
a particular focus on the booming medical weight loss and GLP-1 markets.
MedWell USA will be focused on the
development of innovative weight loss and wellness management solutions,
targeting B2B clients such as medical offices, fitness facilities and wellness
clinics. This approach is designed to meet emerging consumer demands and
capitalize on the significant growth within the global health and wellness
industry.
Paid news dissemination for INTV
Read this news, featuring INTV in
full at https://www.investorideas.com/news/2024/biotech/08281GLP-1-Products-and-Players.asp
Steve Rubakh, CEO of Integrated
Ventures, comments: “This strategic entry represents a significant evolution
for our company. The health and wellness sector offers immense growth
potential, and we are eager to bring unique and impactful solutions (B2B and
B2C) to market that will meet the critical needs of consumers seeking to
improve their health and well-being. According to UB Securities (*) forecast,
the combined GLP-1 market for obesity and diabetes will reach $129 billion by
2029, with 40 million users (with 44% based in USA) and a robust compound
annual growth rate (CAGR) of 30%.”
(*) https://www.ubs.com/global/en/investment-bank/in-focus/2024/glp-1-a-medication.html
In addition to launching MedWell USA,
the Company is in the process of establishing two more subsidiaries aimed at
broadening its weight loss related operations. Furthermore, the Company is
finalizing strategic joint ventures that will enable INTV to quickly and
effectively penetrate the lucrative health and wellness market.
Integrated Ventures is committed to
driving shareholder value by seizing high-growth opportunities within the
health and wellness sector. The Company will provide regular updates as it
advances its strategic plans and achieves key milestones.
In May, Hims & Hers Health, Inc., (NYSE: HIMS) the leading
health and wellness platform, announced the addition of
GLP-1 injections to its comprehensive weight loss portfolio, giving customers
an affordable way to consistently access safe, high-quality weight loss
treatment.
From the news: The company now
offers access to GLP-1 injections in addition to weight management oral
medication kits, so that customers can truly personalize their weight loss
experience. Providing access to compounded GLP-1s means eligible customers can
use medications with the same active ingredient as Ozempic® and Wegovy® without
navigating the shortages and costs that are currently limiting access to the
branded medications. Through a partnership with a leading US manufacturer of
generic and 503B compounded injectable medications, Hims & Hers can help
millions of Americans who have obesity and are looking for help safely managing
their weight.
"The core of our business is to offer a truly
personalized experience that customers can trust and rely on," said Andrew
Dudum, CEO and co-founder of Hims & Hers. "We’ve leveraged our size
and scale to secure access to one of the highest-quality supplies of compounded
GLP-1 injections available today. We’re passing that access and value along to
our customers, who deserve the highest standard of clinical safety and efficacy
to meet their goals, and we're doing it in a safe, affordable way that others
can’t deliver."
Continued: According to the US Food
and Drug Administration (FDA), around 70% of American adults have obesity or
are overweight, and losing 5 to 10% of that body weight can reduce
weight-related health risks, such as diabetes and cardiovascular disease. GLP-1
medications can support healthy weight loss along with a reduced calorie diet
and increased exercise by helping manage blood sugar levels, curb cravings and
suppress appetite, so people eat less without feeling deprived.
In June, Viking Therapeutics, Inc. (NASDAQ: VKTX), a
clinical-stage biopharmaceutical company focused on the development of novel
therapies for metabolic and endocrine disorders, announced the presentation
of preclinical data from a series of internally developed dual agonists of the
amylin and calcitonin receptors at the 84th Scientific Sessions of the American
Diabetes Association. The presentation
highlighted the effects of treatment on body weight, food intake and metabolic
profile in healthy rats and diet-induced obese (DIO) mice as compared to
control cohorts treated with vehicle or the dual amylin and calcitonin receptor
agonist cagrilintide. The studies were
summarized in a poster presentation at the annual scientific conference of the
American Diabetes Association, held in Orlando, Florida in June of this year,
From the news: The study
results demonstrate that Viking's series of dual amylin and calcitonin receptor
agonists (DACRAs) reduced food intake in lean rats in the period from 0 – 72
hours following a single subcutaneous dosing.
At 72 hours following a single subcutaneous dose, Viking's novel
compounds resulted in up to 8% body weight reductions compared to
vehicle-treated animals.
Continued: In a DIO mouse model,
treatment with Viking's series of co-agonists for 24 days resulted in body
weight reductions that were comparable to those achieved in
cagrilintide-treated animals.
Additionally, improvements in key metabolic markers, including blood
glucose levels, were observed in DIO mice treated with the company's compounds
for the 24-day time period.
Looking at the future for the sector, Research and
Markets notes, “The companies are currently aiming on geographical expansion
for increasing the sales output. Novo Nordisk (NYSE: NVO) is expanding its
business by investing in the manufacturing unit located in North Carolina. The
company holds around 50.0% of the market share of GLP-1 receptor agonists and
is expected to dominate the market over the forecast period. Furthermore, in
July 2018, Sanofi invested about USD 74.1 million in China for establishing an
R&D hub to enhance its global reach.”
Continued: “The companies
are also focusing on getting approval for other indications like obesity and
major adverse cardiovascular events by authorities like the U.S.FDA, EMEA and
others for the existing products to increase their life cycle.”
Research and find more biotech stocks at Investorideas.com
https://www.investorideas.com/BIS/Stock_List.asp
Research health and wellness stocks at Investorideas.com
https://www.investorideas.com/LOHAS-investing/Stock_List.asp
About Investorideas.com
Investorideas.com is the go-to platform for big
investing ideas. From breaking stock news to top-rated investing podcasts, we
cover it all. Our original branded content includes podcasts such as Exploring
Mining, Cleantech, Crypto Corner, Cannabis News, and the AI Eye. We also create
free investor stock directories for sectors including mining, crypto, renewable
energy, gaming, biotech, tech, sports and more.
Disclaimer/Disclosure: This news article featuring - Integrated
Ventures, Inc. (OTCQB: INTV) is a paid for news release
creation and dissemination on Investorideas.com. Our site does not
make recommendations for purchases or sale of stocks, services or
products. This is not investment
opinion: Nothing on our sites should be construed as an offer or solicitation
to buy or sell products or securities. All investing involves risk and possible
losses. More disclaimer info: https://www.investorideas.com/About/Disclaimer.asp Learn more about publishing your
news release and our other news services and prices on the Investorideas.com
newswire https://www.investorideas.com/News-Upload/ Global investors must adhere to
regulations of each country. Privacy policy: https://www.investorideas.com/About/Private_Policy.asp
Follow us on Facebook https://www.facebook.com/Investorideas
Follow us on
YouTube https://www.youtube.com/c/Investorideas
Contact Investorideas.com
800-665-0411
Biotech Industry Stocks- investing ideas in biotechnology
stocks, medical technology and life sciences
Get more biotech and medical tech news, articles,
podcasts and stock directories
Health, wellness and sustainability stocks - Get more HWS news, articles and stock directories
